Pharma News - Research & Development News & Articles

641 Pharmaceutical Organizations Announce Key Principles to Foster Supply Chain Security and Integrity Full Text PhRMA, February 4, 2013

642 Actavis Details Strategy for Continued Long-Term Growth Full Text Actavis, February 4, 2013

643 RAPID-PsA study showed that certolizumab pegol improved the signs and symptoms of psoriatic arthritis Full Text UCB, February 4, 2013

644 RAPID-PsA study showed that certolizumab pegol improved signs and symptoms of psoriatic arthritis in patients with and without prior anti-TNF exposure Full Text UCB, February 4, 2013

645 Observational study in routine clinical practice setting showed that Neupro (rotigotine transdermal patch) improved day- and night-time symptoms of Restless Legs Syndrome Full Text UCB, February 4, 2013

646 UCB Announces New Data to Increase Understanding of Short- and Long-Term Clinical Profile of Antiepileptic Drug VIMPAT (lacosamide) Full Text UCB, February 4, 2013

647 Post-hoc analysis indicated that timing and magnitude of initial response to certolizumab pegol predicted likelihood of low disease activity at week 28 in patients with active moderate to severe rheumatoid arthritis Full Text UCB, February 4, 2013

648 Obinutuzumab (GA101) significantly improved progression-free survival in people with chronic lymphocytic leukemia (CLL) Full Text Roche, February 1, 2013

649 Press Release (January 30, 2013) Obinutuzumab (GA101) Significantly Improved Progression-Free Survival in People with Chronic Lymphocytic Leukemia (CLL) Full Text Genentech, February 1, 2013

650 Cell Therapeutics Announces Data Safety and Monitoring Board Recommendation to Continue the GOG-0212 Phase 3 Clinical Trial of OPAXIOTM as Maintenance Therapy in Ovarian Cancer Full Text Cell Therapeutics, February 1, 2013

651 UCB and Amgen Initiate Sclerostin Antibody Phase 3 program in patients with postmenopausal osteoporosis Full Text UCB, February 1, 2013

652 UCB announces data on Cimzia (certolizumab pegol) for patients with moderate to severe rheumatoid arthritis at American College of Rheumatology 2012 Congress Full Text UCB, February 1, 2013

653 New Peer-reviewed Publication Offers Guidance for Integrating Gattex (Teduglutide [rDNA origin]) for Injection into Management of Short Bowel Syndrome Full Text NPS Pharmaceuticals, January 31, 2013

654 FDA Advisory Committee Recommends Approval for Boehringer Ingelheims Olodaterol* for Maintenance Treatment of COPD Full Text Boehringer Ingelheim, January 31, 2013

655 Neupro (rotigotine transdermal patch) approved in Japan for Parkinsons disease and Restless Legs Syndrome Full Text UCB, January 31, 2013

656 Genzyme and Isis Announce FDA Approval of KYNAMRO (mipomersen sodium) Injection for the Treatment of Homozygous Familial Hypercholesterolemia Full Text Sanofi, January 31, 2013

657 UCB and Amgen announce positive phase 2 results of CDP7851/AMG785 in patients with post menopausal osteoporosis (PMO) Full Text UCB, January 31, 2013

658 Astellas and UCB announce approval of Cimzia (certolizumab pegol) in Japan for the treatment of adult patients with rheumatoid arthritis Full Text UCB, January 31, 2013

659 Aveo and astellas announce presentations of tivozanib clinical data at 2013 asco genitourinary cancers symposium Full Text Astellas, January 31, 2013

660 New RAPID 1 post-hoc analysis showed early response to Cimzia (certolizumab pegol) at Week 12 was predictive of Week 52 response Full Text UCB, January 31, 2013